Format

Send to

Choose Destination
SLAS Discov. 2019 Jan;24(1):57-67. doi: 10.1177/2472555218792264. Epub 2018 Aug 7.

Development of a Screening Platform to Identify Small Molecules That Modify ELP1 Pre-mRNA Splicing in Familial Dysautonomia.

Author information

1
1 Center for Genomic Medicine, Massachusetts General Hospital Research Institute, Boston, MA, USA.
2
2 Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
3
3 Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.
4
4 Byrd Alzheimer's Institute College of Medicine Department of Molecular Pharmacology & Physiology, University of South Florida, Tampa, FL, USA.
5
5 NuPharmAdvise LLC, Sanbornton, NH, USA.
6
6 In Vitro Strategies LLC, Flemington, NJ, USA.

Abstract

Familial dysautonomia (FD) is an autonomic and sensory neuropathy caused by a mutation in the splice donor site of intron 20 of the ELP1 gene. Variable skipping of exon 20 leads to a tissue-specific reduction in the level of ELP1 protein. We have shown that the plant cytokinin kinetin is able to increase cellular ELP1 protein levels in vivo and in vitro through correction of ELP1 splicing. Studies in FD patients determined that kinetin is not a practical therapy due to low potency and rapid elimination. To identify molecules with improved potency and efficacy, we developed a cell-based luciferase splicing assay by inserting renilla (Rluc) and firefly (Fluc) luciferase reporters into our previously well-characterized ELP1 minigene construct. Evaluation of the Fluc/Rluc signal ratio enables a fast and accurate way to measure exon 20 inclusion. Further, we developed a secondary assay that measures ELP1 splicing in FD patient-derived fibroblasts. Here we demonstrate the quality and reproducibility of our screening method. Development and implementation of this screening platform has allowed us to efficiently screen for new compounds that robustly and specifically enhance ELP1 pre-mRNA splicing.

KEYWORDS:

compounds; familial dysautonomia; luciferase assay; splicing assay

PMID:
30085848
DOI:
10.1177/2472555218792264

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center